Preclinical evaluation of anti-HER2 Affibody molecules site-specifically labeled with 111In using a maleimido derivative of NODAGA

Nuclear Medicine and Biology

Volumn 39, Issue 4, 2012, Pages 518-529

  Altai, Mohamed ^a   Perols, Anna ^b   Karlström, Amelie Eriksson ^b   Sandström, Mattias ^c   Boschetti, Frederic ^d   Orlova, Anna ^e   Tolmachev, Vladimir ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b ROYAL INSTITUTE OF TECHNOLOGY   (Sweden)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^d CheMatech ^*  (France)

^e UPPSALA UNIVERSITY   (Sweden)

Author keywords

Affibody molecules; HER2; Indium 111; Maleimido NODAGA; Molecular imaging; Radionuclides; Receptor targeting

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; INDIUM MALEIMIDOETHYLMONOAMIDE 1,4,7 TRIAZACYCLONONANE 1 GLUTARIC ACID 4,7 DIACETIC ACID AFFIBODY Z HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR TYPE 2:2395 [61 CYSTEINE] IN 111; INDIUM MALEIMIDOETHYLMONOAMIDE 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID AFFIBODY Z HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR TYPE 2:2395 [61 CYSTEINE] IN 111; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; ISOTOPE ANALYSIS; ISOTOPE LABELING; MALE; MOLECULAR IMAGING; MOUSE; NONHUMAN; PROCESS DEVELOPMENT; PROTEIN EXPRESSION; PROTEIN TARGETING; RADIOISOTOPE DISTRIBUTION; TUMOR SCINTISCANNING;

ACETIC ACIDS; ANIMALS; ANTIBODIES, MONOCLONAL; BINDING SITES; CELL LINE, TUMOR; CHELATING AGENTS; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; INDIUM RADIOISOTOPES; ISOTOPE LABELING; MALE; MALEIMIDES; MICE; RECEPTOR, ERBB-2; RECOMBINANT FUSION PROTEINS; SUBSTRATE SPECIFICITY; SULFHYDRYL COMPOUNDS;

EID: 84860342736     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2011.10.013     Document Type: Article

References (46)

1. Citri A., Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 2006, 7:505-516.
2. Hynes N.E., Lane H.A. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005, 5:341-354.
3. Guarneri V., Barbieri E., Dieci M.V., Piacentini F., Conte P. Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer. Cancer Treat Rev 2010, 36(Suppl 3):S62-S66.
4. Bang Y.J., Van Cutsem E., Feyereislova A., Chung H.C., Shen L., Sawaki A., et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010, 376:687-697.
5. Tolmachev V., Stone-Elander S., Orlova A. Radiolabeled receptor-tyrosine-kinase targeting drugs for patient stratification and monitoring of therapy response: prospects and pitfalls. Lancet Oncol 2010, 11:992-1000.
6. Behr T.M., Béhé M., Wörmann B. Trastuzumab and breast cancer. N Engl J Med 2001, 345:995-996.
7. Perik P.J., Lub-De Hooge M.N., Gietema J.A., van der Graaf W.T., de Korte M.A., Jonkman S., et al. Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 2006, 24:2276-2282.
8. Wahl R.L., Parker C.W., Philpott G.W. Improved radioimaging and tumor localization with monoclonal F(ab')2. J Nucl Med 1983, 24:316-325.
9. Andrew S.M., Perkins A.C., Pimm M.V., Baldwin R.W. A comparison of iodine and indium labeled anti CEA intact antibody, F(ab)2 and Fab fragments by imaging tumour xenografts. Eur J Nucl Med 1988, 13:598-604.
10. Schmidt M.M., Wittrup K.D. A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Mol Cancer Ther 2009, 8:2861-2871.
11. Nygren P.A. Alternative binding proteins: affibody binding proteins developed from a small three-helix bundle scaffold. FEBS J 2008, 275:2668-2676.
12. Löfblom J., Feldwisch J., Tolmachev V., Carlsson J., Ståhl S., Frejd F.Y. Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications. FEBS Lett 2010, 584:2670-2680.
13. Orlova A., Magnusson M., Eriksson T.L., Nilsson M., Larsson B., Höidén-Guthenberg I., et al. Tumor imaging using a picomolar affinity HER2 binding affibody molecule. Cancer Res 2006, 66:4339-4348.
14. Friedman M., Orlova A., Johansson E., Eriksson T.L., Höidén-Guthenberg I., Tolmachev V., et al. Directed evolution to low nanomolar affinity of a tumor-targeting epidermal growth factor receptor-binding affibody molecule. J Mol Biol 2008, 376:1388-1402.
15. Li J., Lundberg E., Vernet E., Larsson B., Höidén-Guthenberg I., Gräslund T. Selection of affibody molecules to the ligand-binding site of the insulin-like growth factor-1 receptor. Biotechnol Appl Biochem 2010, 55:99-109.
16. Lindborg M., Cortez E., Höidén-Guthenberg I., Gunneriusson E., von Hage E., Syud F., et al. Engineered high-affinity affibody molecules targeting platelet-derived growth factor receptor β in vivo. J Mol Biol 2011, 407:298-315.
17. Ahlgren S., Tolmachev V. Radionuclide molecular imaging using Affibody molecules. Curr Pharm Biotechnol 2010, 11:581-589.
18. Tolmachev V. Imaging of HER-2 overexpression in tumors for guiding therapy. Curr Pharm Des 2008, 14:2999-3019.
19. Orlova A., Wållberg H., Stone-Elander S., Tolmachev V. On the selection of a tracer for PET imaging of HER2-expressing tumors: direct comparison of a 124I-labeled affibody molecule and trastuzumab in a murine xenograft model. J Nucl Med 2009, 50:417-425.
20. Malmberg J., Sandström M., Wester K., Tolmachev V., Orlova A. Comparative biodistribution of imaging agents for in vivo molecular profiling of disseminated prostate cancer (PC) in mice bearing PC xenografts: focus on 111In- and 125I-labeled anti-HER2 humanized monoclonal trastuzumab and ABY-025. Nucl Med Biol 2011, 38:1093-1102.
21. Baum R.P., Prasad V., Müller D., Schuchardt C., Orlova A., Wennborg A., et al. Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In- or 68Ga-labeled affibody molecules. J Nucl Med 2010, 51:892-897.
22. Engfeldt T., Tran T., Orlova A., Widström C., Feldwisch J., Abrahmsen L., et al. 99mTc-chelator engineering to improve tumour targeting properties of a HER2-specific Affibody molecule. Eur J Nucl Med Mol Imaging 2007, 34:1843-1853.
23. Tran T., Engfeldt T., Orlova A., Sandström M., Feldwisch J., Abrahmsén L., et al. (99m)Tc-maEEE-Z(HER2:342), an Affibody molecule-based tracer for the detection of HER2 expression in malignant tumors. Bioconjug Chem 2009, 18:1956-1964.
24. Wållberg H., Ahlgren S., Widström C., Orlova A. Evaluation of the radiocobalt-labeled [MMA-DOTA-Cys61]-Z HER2:2395(-Cys) affibody molecule for targeting of HER2-expressing tumors. Mol Imaging Biol 2010, 12:54-62.
25. Tolmachev V., Velikyan I., Sandström M., Orlova A. A HER2-binding Affibody molecule labeled with 68Ga for PET imaging: direct in vivo comparison with the 111In-labeled analogue. Eur J Nucl Med Mol Imaging 2010, 37:1356-1367.
26. Tolmachev V., Feldwisch J., Lindborg M., Baastrup B., Sandström M., Orlova A. Influence of an aliphatic linker between DOTA and synthetic Z(HER2:342) Affibody molecule on targeting properties of the (111)In-labeled conjugate. Nucl Med Biol 2011, 8:697-706.
27. Tolmachev V., Altai M., Sandström M., Perols A., Karlstro m A.E., Boschett F., et al. Evaluation of a maleimido derivative of NOTA for site-specific labeling of Affibody molecules. Bioconjug Chem 2011, 22:894-902.
28. 3](+), and shows improved biodistribution with reduced hepatic radioactivity accumulation. Bioconjug Chem 2010, 21:2013-2202.
29. Ekblad T., Tran T., Orlova A., Widström C., Feldwisch J., Abrahmsén L., et al. Development and preclinical characterisation of 99mTc-labeled Affibody molecules with reduced renal uptake. Eur J Nucl Med Mol Imaging 2008, 35:2245-2255.
30. Wållberg H., Orlova A., Altai M., Hosseinimehr S.J., Widström C., Malmberg J., et al. Molecular design and optimization of 99mTc-labeled recombinant affibody molecules improves their biodistribution and imaging properties. J Nucl Med 2011, 52:461-469.
31. Altai M., Wållberg H., Orlova A., Rosestedt M., Hosseinimehr S.J., Tolmachev V. Order of amino acids in C-terminal cysteine-containing peptide-based chelators influences cellular processing and biodistribution of (99m)Tc-labeled recombinant Affibody molecules. Amino Acids 2011, 10.1007/s00726-011-0927-x.
32. Jorda M., Morales A., Ghorab Z., Fernandez G., Nadji M., Block N. Her2 expression in prostatic cancer: a comparison with mammary carcinoma. J Urol 2002, 168:1412-1414.
33. Reese D.M., Small E.J., Magrane G., Waldman F.M., Chew K., Sudilovsky D. HER2 protein expression and gene amplification in androgen-independent prostate cancer. Am J Clin Pathol 2001, 116:234-239.
34. Eisenwiener K.P., Prata M.I., Buschmann I., Zhang H.W., Santos A.C., Wenger S. NODAGATOC, a new chelator-coupled somatostatin analogue labeled with [67/68Ga] and [111In] for SPECT, PET, and targeted therapeutic applications of somatostatin receptor (hsst2) expressing tumors. Bioconjug Chem 2002, 13:530-541.
35. Velikyan I., Maecke H., Langstrom B. Convenient preparation of 68Ga-based PET-radiopharmaceuticals at room temperature. Bioconjug Chem 2008, 19:569-573.
36. Velikyan I., Beyer G.J., Bergström-Pettermann E., Johansen P., Bergström M., Långström B. The importance of high specific radioactivity in the performance of 68Ga-labeled peptide. Nucl Med Biol 2008, 35:529-536.
37. Knetsch P.A., Petrik M., Griessinger C.M., Rangger C., Fani M., Kesenheimer C., et al. [(68)Ga]NODAGA-RGD for imaging α(v)β (3) integrin expression. Eur J Nucl Med Mol Imaging 2011, 38:1303-1312.
38. Ahlgren S., Orlova A., Rosik D., Sandström M., Sjöberg A., Baastrup B. Evaluation of maleimide derivative of DOTA for site-specific labeling of recombinant Affibody molecules. Bioconjug Chem 2008, 19:235-243.
39. Tolmachev V., Xu H., Wållberg H., Ahlgren S., Hjertman M., Sjöberg A. Evaluation of a maleimido derivative of CHX-A″ DTPA for site-specific labeling of affibody molecules. Bioconjug Chem 2008, 19:1579-1587.
40. Persson M., Tolmachev V., Andersson K., Gedda L., Sandstrom M., Carlsson J. [177Lu]pertuzumab: experimental studies on targeting of HER-2 positive tumour cells. Eur J Nucl Med Mol Imaging 2005, 32:1457-1462.
41. Malmberg J., Tolmachev V., Orlova A. Imaging agents for in vivo molecular profiling of disseminated prostate cancer: cellular processing of [111In]-labeled CHX-A″ DTPA-trastuzumab and anti-HER2 ABY-025 Affibody in prostate cancer cell lines. Exp Ther Med 2011, 2:523-528.
42. Wållberg H., Orlova A. Slow internalization of anti-HER2 synthetic affibody monomer 111In-DOTA-ZHER2:342-pep2: implications for development of labeled tracers. Cancer Biother Radiopharm 2008, 23:435-442.
43. Tolmachev V., Orlova A. Influence of labelling methods on biodistribution and imaging properties of radiolabeled peptides for visualisation of molecular therapeutic targets. Curr Med Chem 2010, 17:2636-2655.
44. Ziada A., Barqawi A., Glode L.M., Varella-Garcia M., Crighton F., Majeski S., et al. The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial. Prostate 2004, 60:332-337.
45. Tran T.A., Rosik D., Abrahmsén L., Sandström M., Sjöberg A., Wållberg H., et al. Design, synthesis and biological evaluation of a multifunctional HER2-specific Affibody molecule for molecular imaging. Eur J Nucl Med Mol Imaging 2009, 36:1864-1873.
46. Tolmachev V., Mume E., Sjöberg S., Frejd F.Y., Orlova A. Influence of valency and labelling chemistry on in vivo targeting using radioiodinated HER2-binding. Eur J Nucl Med Mol Imaging 2009, 36:692-701.